Web9 uur geleden · PRINCETON, N.J., April 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company convened a Type A Meeting with the … WebA Phase 3 trial indicates HyBryte, developed by Soligenix, could be an effective treatment for cutaneous T-cell lymphoma (CTCL). The poster abstract was selected as a “top …
Soligenix Announces Scheduling of Type A Meeting with the U.S.
Web20 jul. 2024 · HyBryte ™ potentially represents the safest available efficacious treatment for CTCL. With no systemic absorption, a compound that is not mutagenic and a light … Web7 dec. 2024 · This PIP waiver will allow them to work toward marketing authorization for their novel therapy called HyBryte, a treatment for cutaneous T-cell lymphoma (CTCL) … bourne end turkish barbers
FDA Asks For Additional Successful Trial To Approve Soligenix
Web3 uur geleden · During a type a meeting between Soligenix, Inc., and the FDA, discussed the contents of a refusal to file letter previously issued by the FDA regarding the new … Web10 jun. 2024 · Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency News provided by. Soligenix, Inc. Jun 10, … Web1 jan. 2024 · Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (response 42%, p<0.0001 relative to placebo treatment in Cycle 1) … bourne end \u0026 henley security systems ltd